Background/Aim: As chronic inflammation underlies both atherosclerosis and malnutrition, a possible link between these factors has been suggested in hemodialysis (HD) patients. We designed this study to compare nutritional indices and inflammatory parameters of HD patients with demonstrated atherosclerosis (group I) and HD patients without (group II). Methods: We included 59 and 57 patients in groups I and II, respectively. The patient groups were matched for the risk factors for atherosclerosis such as age, gender, smoking habits, hypertension, and HD duration. The nutritional status of the patients was evaluated according to laboratory parameters, normalized protein catabolic rate, anthropometric measurements, and subjective global assessment. Results: Laboratory parameters (albumin, prealbumin, total cholesterol, phosphorus, creatinine), normalized protein catabolic rate, and triceps skinfold thickness revealed a significant decline in the nutritional status of the patients with atherosclerosis. We found that the patients with atherosclerosis had significantly higher C-reactive protein, ferritin, and fibrinogen levels when we compared the patient groups for acute-phase reactants. When we assessed malnutrition as being in category B/C (B = mild to moderately malnourished, C = severely malnourished) according to subjective global assessment and inflammation on the basis of a C-reactive protein level ≧10 mg/l, among patients with atherosclerosis, there was a significantly higher proportion of them having malnutrition and inflammation. Additionally, the proportion of patients without any evidence of malnutrition and inflammation was significantly lower in group I than in group II. Conclusion: Our study gives evidence for the possible triad of malnutrition, inflammation, and atherosclerosis in HD patients.

Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853–906.
Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353–362.
Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000;35(4 suppl 1):117–131.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
Hakim RM, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 1993;21:125–137.
Bergström J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995;6:1329–1341.
Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagi H: Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998;31:93–100.
Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899–1991.
Kaysen GA: Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9:2368–2376.
Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953–960.
Bergström J, Lindholm B: Malnutrition, cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis 1998;32:834–841.
Ikizler TA, Hakim RM: Nutrition in end-stage renal disease. Kidney Int 1996;50:343–357.
Daugirdas JT: Second-generation logarithmic estimates of single-pool variable volume Kt/V: An analysis error. J Am Soc Nephrol 1993;4:1205–1213.
McCann L: Using subjective global assessment to identify malnutrition in the ESRD patient. Nephrol News Issues 1999;13:18–19.
Enia G, Sicuso C, Alati G, Zoccali C: Subjective global assessment of nutrition in dialysis patients. Nephrol Dial Transplant 1993;8:1094–1098.
Visser R, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Reliability of the 7-point subjective global assessment scale in assessing nutritional status of dialysis patients. Adv Perit Dial 1999;15:222–225.
Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergström J: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 1998;53:773–782.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Hypoalbuminemia, cardiac morbidity, and mortality in end stage renal disease. J Am Soc Nephrol 1996;7:728–736.
Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis: Report of the Diaphane Collaborative Study. Nephron 1982;31:103–110.
Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107–114.
Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482.
Rosenson RS: Myocardial injury: The acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993;22:933–940.
Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M: Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989;78:145–150.
Bergström J, Heimbürger O, Lindholm B, Qureshi AR: Elevated serum CRP is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients (abstract). J Am Soc Nephol 1995;6:573.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enchances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648–658.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.